ARZERRA® (ofatumumab)

Press Release

> April 17, 2014 – GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as
first-line treatment in combination with chlorambucil for patients with Chronic
Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered
inappropriate

Multimedia

Download hi-res jpg images

Note to user, 'Right click', 'Save Target As' to download image.